Heparin Binding to Plasma Proteins, an Important Mechanism for Heparin Resistance

Summary

Heparin dosage requirements vary widely among patients with venous thromboembolism. In this study, we measured the proportion of anticoagulantly-active heparin which was reversibly bound and neutralized by plasma proteins (defined as reversible heparin neutralization) in the pre-treatment plasma (in vitro) and in the 6 h post-treatment plasma (ex vivo) of patients with venous thromboembolism treated with a fixed dose of heparin. Reversible heparin neutralization was assessed by comparing the heparin levels measured as anti-factor Xa activity before and after the addition of low affinity heparin which is essentially devoid of antifactor Xa activity, in order to displace heparin bound to plasma proteins. The results indicate that reversible heparin neutralization due to binding to plasma proteins is a major determinant of the anticoagulant response to a fixed dose of standard heparin 6 h post-treatment and of the eventual heparin dose required to achieve a therapeutic anticoagulant effect on days 3-5 of heparin treatment.

• References

• 1 Hull RD, Raskob GE, Hirsh J, Jay RM, LeClerc JR, Geerts WH, Rosenbloom D, Sackett DL, Anderson C, Harrison L, Gent M. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986; 315: 1109-1114
• 2 Basu D, Gallus A, Hirsh J, Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 1972; 287: 324-327
• 3 Hirsh J, Van Aken WG, Gallus AS, Dollery CT, Cade JF, Yung WJ. Heparin kinetics in venous thrombosis and pulmonary embolism. Circulation 1976; 53: 691-695
• 4 Chiu HM, Hirsh J, Yung WJ, Regoeczi E, Gent M. Relationship between the anticoagulant and antithrombotic effects of heparin in experimental venous thrombosis. Blood 1977; 49: 171-184
• 5 Hirsh J. Mechanism of action and monitoring of anticoagulants. Semin Thromb Haemostas 1986; 12: 1-11
• 6 Cruickshank MK, Levine MN, Hirsh J, Roberts R, Siguenza M. A standard heparin nomogram for the management of heparin therapy. Arch Intern Med 1991; 151: 333-337
• 7 Boneu B, Caranobe C, Cadroy Y, Dol F, Gabaig AM, Dupouy D, Sie P. Pharmacokinetic studies of standard unfractionated heparin, and low molecular weight heparins in the rabbit. Semin Thromb Hemostas 1988; 14: 18-27
• 8 Edson VR, Krivit W, White JG. Kaolin partial thromboplastin time: High levels of procoagulants producing short clotting times or masking deficiencies of other procoagulants or low concentrations of anticoagulants. J Lab Clin Med 1967; 70: 463-470
• 9 Levine SP, Sorenson RR, Harris MA, Knieriem LK. The effect of platelet factor 4 (PF4) on assays of plasma heparin. Br J Haematol 1984; 57: 585-596
• 10 Lijnen HR, Hoylaerts M, Collen D. Heparin binding properties of human histidine-rich glycoprotein. Mechanism and role in the neutralization of heparin in plasma. J Biol Chem 1983; 258: 3803-3808
• 11 Lane DA. Heparin binding and neutralizing proteins. In: Heparin, Chemical and Biological Properties, Clinical Applications. Lane DA, Lindahl U. (eds) CRC Press Inc.; Boca Raton, CA: 1989. pp 363-391
• 12 Casu B, Diamantini G, Fedeli G, Mantovani M, Oreste P, Pescador R, Porta R, Prino G, Torri G, Zoppetti G. Retention of antilipemic activity by periodated-oxidized non-anticoagulant heparins. Arzneim Forsch/Drug Res 1986; 36: 637-642
• 13 Young E, Hirsh J. Contribution of red blood cells to the saturable mechanism of heparin clearance. Thromb Haemostas 1990; 64: 559-563
• 14 Young E, Petrowski P, Hirsh J. Glycosaminoglycans displace anticoa-gulantly-active heparin from plasma protein binding sites. Thromb Haemostas 1991; 65: 933 (Abstr)
• 15 Teien AN, Lie M. Evaluation of an amidolytic heparin assay method: increased sensitivity by adding purified antithrombin III. Thromb Res 1977; 10: 399-410
• 16 Young E. The monitoring of low molecular weight (LMW) heparins in the clinical chemistry laboratory. Abstracts of the 4th Asian-Pacific Congress of Clinical Biochemistry 1988; p 160
• 17 Barzu T, van Rijn JLML, Petitou M, Molho P, Tobelem G, Caen JP. Endothelial binding sites for heparin. Specificity and role in heparin neutralization. Biochem J 1986; 238: 847-854
• 18 van Rijn JLML, Trillou M, Mardiguian J, Tobelem G, Caen J. Selective binding of heparins to human endothelial cells. Implications for pharmacokinetics. Thromb Res 1987; 45: 211-222
• 19 Leung L, Saigo K, Grant D. Heparin binds to human monocytes and modulates their procoagulant activities and secretory phenotypes. Effect of histidine-rich glycoprotein. Blood 1989; 73: 177-184
• 20 Talstad I. Heparin therapy adjusted for body weight. Am J Clin Pathol 1985; 83: 378-381